Mortality rates decrease, chronic disease rates increase among HIV+ ICU patients

May 23, 2012

The expanded use of antiretrovirals, potent drugs used to treat retroviral infections such as human immunodeficiency virus (HIV), has been linked to significant decreases in hospital mortality rates among severely ill HIV-positive(HIV+) patients nationwide, primarily due to a decrease in opportunistic infections, according to a new study by researchers at Stanford University. Despite these encouraging data, the study also revealed that in this population, chronic diseases and bloodstream infections are on the rise.

The study results will be presented at the ATS 2012 International Conference in San Francisco.

"The national expansion of antiretroviral programs has appeared to yield benefits well beyond the outpatient setting," said study lead author Monica Bhargava, MD, MS, adjunct in Stanford University's Division of Pulmonary and . "In the 1980s, HIV+ were often declined ICU admission because their prognosis was deemed far too grave. Our work shows that this has changed substantially since the advent of the antiretroviral era. The broader use of such medications is having a wide-ranging impact."

Although previous studies have shown that the initiation in the mid-1990s of antiretroviral therapy (ART) for the treatment of HIV has led to sharp reductions in mortality across the United States, Dr. Bhargavasaid that until now, the effect on critically ill HIV+ patients had not been assessed with a nationally-representative sample.

"We wanted to examine the impact of the ART era on in-hospital mortality among critically ill HIV+ patients, particularly those requiring mechanical ventilation, using a nationwide sample," she said. "We also wanted to evaluate hospital length of stay (LOS), and the prevalence of selected diseases among these patients."

For their study, the researchers used data spanning the 16-year period from 1993 to 2008, culled from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS), a database of hospital inpatient stays used by researchers and policymakers to identify, track and analyze national trends in health care. For each year, statistical analyses were performed to isolate the effect of HIV+ status on mortality, controlling for socioeconomic, demographic and hospital characteristics.

"We found that, although nationally, the number of HIV+ requiring mechanical ventilation rose from 7,632 in 1993 to 10,775 in 2008, mortality in that population declined from over 63 percent in 1993 to 41.4 percent in 2008, with the sharpest decline occurring in 1996-1997, the beginning of the ART era," Dr. Bhargava said.

This decrease is most likely due to the concomitant decline in the occurrence of opportunistic infections, which are less likely in those on antiretroviral drugs, Dr. Bhargava said.In this study, Dr. Bhargavalooked at one such infection commonly associated with patients on mechanical ventilation, Pneumocystis carinii pneumonia (PCP), and found that among HIV+ patients who received , the rates of PCP infection nearly halved, from 29.2 percent in 1993 to 15.2 percent in 2008.

"It appears that the wider use of antiretroviral therapy has both decreased the percentage of patients with PCP and reduced mortalityin those patients who develop it," Dr. Bhargava said. "That is quite encouraging."

The researchers also found that median length of hospital stay declined in the HIV+ population during the study period, and this population also experienced a slower rate of growth in hospital charges relative to the general population. Black race remained the strongest independent predictor of in-hospital death.

"Our study confirms that major gains in in-hospital survival have occurred among HIV+ patients with respiratory failure, though there is still much more progress that needs to be made," Dr. Bhargava said. "In addition, there has been a notable increase in the diagnoses of sepsis, chronic obstructive airway disease, liver disease and coronary artery disease.

"Our work shows that our national efforts should focus more on managing and sepsis in this population," she added. "Future studies should help clarify the reasons behind the surge in sepsis and why ICU survival remains poorer among HIV+ ethnic minorities."

Explore further: HIV rate in SF could be cut sharply with expanded treatment, study predicts

More information: "HIV In The ICU: National Outcomes Of Patients In The ART Era" (Session D102, Wednesday, May 23, Room 131, Moscone Center; Abstract 31769)

Related Stories

HIV rate in SF could be cut sharply with expanded treatment, study predicts

April 13, 2011
If HIV-infected adults in San Francisco began taking antiretroviral treatments as soon as they were diagnosed, the rate of new HIV infections among men who have sex with men would be cut by almost 6o percent over five years, ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.